{"nctId":"NCT02668653","briefTitle":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","startDateStruct":{"date":"2016-09-01","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia","Leukemia"],"count":539,"armGroups":[{"label":"Chemotherapy plus quizartinib","type":"EXPERIMENTAL","interventionNames":["Drug: Chemotherapy","Drug: Quizartinib"]},{"label":"Chemotherapy plus placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Chemotherapy","Drug: Placebo"]}],"interventions":[{"name":"Chemotherapy","otherNames":["Cytarabine","Daunorubicin","Idarubicin"]},{"name":"Quizartinib","otherNames":["Test Product"]},{"name":"Placebo","otherNames":["Placebo Control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC) or Institutional Review Board approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests;\n2. Is ≥18 years or the minimum legal adult age (whichever is greater) and ≤75 years (at Screening);\n3. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening);\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (at the time the participant signs their first ICF);\n5. Presence of FLT3-ITD activating mutation in bone marrow (allelic ratio of ≥3% FLT3-ITD/total FLT3);\n6. Participant is receiving standard \"7+3\" induction chemotherapy regimen as specified in the protocol;\n7. Adequate renal function defined as:\n\n   a. Creatinine clearance \\>50 mL/min, as calculated with the modified Cockcroft Gault equation\n8. Adequate hepatic function defined as:\n\n   1. Total serum bilirubin (TBL) ≤1.5 × upper limit of normal (ULN) unless the participant has documented Gilbert's syndrome or the increase is related to increased unconjugated (indirect) bilirubin due to hemolysis;\n   2. Serum alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × ULN;\n9. Serum electrolytes within normal limits: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia or ionized calcium) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected;\n10. If a woman of childbearing potential, must have a negative serum pregnancy test upon entry into this study and must be willing to use highly effective birth control upon enrollment, during the treatment period and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months);\n11. If male, must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later.\n\nExclusion Criteria:\n\n1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).\n2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms;\n3. Prior treatment for AML, except for the following allowances:\n\n   * Leukapheresis;\n   * Treatment for hyperleukocytosis with hydroxyurea;\n   * Cranial radiotherapy for central nervous system (CNS) leukostasis;\n   * Prophylactic intrathecal chemotherapy;\n   * Growth factor/cytokine support;\n4. Prior treatment with quizartinib or other FLT3-ITD inhibitors;\n5. Prior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;\n6. History of known CNS leukemia, including cerebrospinal fluid positive for AML blasts; lumbar puncture is recommended for participants with symptoms of CNS leukemia to rule out extramedullary CNS involvement;\n7. History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for at least 2 years;\n8. Uncontrolled or significant cardiovascular disease, including any of the following:\n\n   * Bradycardia of less than 50 beats per minute, unless the participant has a pacemaker;\n   * Fridericia's Heart Rate Correction Formula (QTcF) interval \\>450 msec;\n   * Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);\n   * Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;\n   * History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);\n   * History of second (Mobitz II) or third degree heart block (participants with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);\n   * History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;\n   * History of New York Heart Association Class 3 or 4 heart failure;\n   * Known history of left ventricular ejection fraction (LVEF) ≤45% or less than the institutional lower limit of normal;\n   * Complete left bundle branch block;\n9. Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;\n10. Known active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C);\n11. Known history of human immunodeficiency virus (HIV). Participants should be tested for HIV prior to Randomization if required by local regulations or EC;\n12. History of hypersensitivity to any excipients in the quizartinib/placebo tablets;\n13. Females who are pregnant or breastfeeding;\n14. Otherwise considered inappropriate for the study by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","description":"Overall survival is defined as the time from randomization until death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","description":"Event-free survival (EFS) is the time from randomization to the earliest date of either refractory disease (or treatment failure \\[TF\\]), relapse, or death from any cause. Refractory disease is defined as complete remission never achieved during Induction (CR: \\>1000 neutrophils, \\>100,000 platelets, \\<5% blasts, and other \\[defined as absence of extramedullary disease \\[EMD\\], blasts with rods, and leukemic blasts\\]). For refractory disease, EFS event date is Day 1 (randomization). Relapse after CR is defined as ≥5% blasts, leukemic blasts, extramedullary leukemia, and presence of rods. This analysis is based on a response assessment with TF defined as not achieving response of CR, using a 42- day window from the start of the last cycle in Induction for CR evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","description":"Complete remission (CR) rate is defined as the percentage of participants achieving CR, defined as \\<5% blasts, \\>1000 neutrophils, \\>100,000 platelets, and other \\[defined as absence of extramedullary disease \\[EMD\\], blasts with rods, and leukemic blasts\\], after induction","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","description":"Composite complete remission (CRc) rate is defined as the percentage of participants whose best response is complete remission (CR), defined as \\<5% blasts, \\>1000 neutrophils, \\>100,000 platelets, and other \\[defined as absence of extramedullary disease \\[EMD\\], blasts with rods, and leukemic blasts\\], or CR with incomplete neutrophil or platelet recovery (CRi) at the end of first Induction cycle.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","description":"A treatment-emergent adverse event (TEAE) is defined as an adverse event that occur, having been absent before first dose of quizartinib or placebo, or have worsened in severity after initiating quizartinib or placebo. Adverse events collected more than 30 days after the last dose of quizartinib/placebo will not be considered TEAEs unless they are considered drug-related.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null},{"groupId":"OG001","value":"265","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"209","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"158","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","description":"Complete remission (CR) is defined as participants achieving CR defined as \\<5% blasts, \\>1000 neutrophils, \\>100,000 platelets, and other \\[defined as absence of extramedullary disease \\[EMD\\], blasts with rods, and leukemic blasts\\]. Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","description":"Composite complete remission (CRc) is defined as \\<5% blasts, \\>1000 neutrophils, \\>100,000 platelets, and other \\[defined as absence of extramedullary disease \\[EMD\\], blasts with rods, and leukemic blasts\\], or CR with incomplete neutrophil or platelet recovery (CRi). Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State","description":"AUCss was assessed by population Pharmacokinetic (PK) analysis during Cycle 1 of each phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2680","spread":"84.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3930","spread":"77.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5080","spread":"74.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10200","spread":"74.7"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)","description":"Css,max was assessed by population PK analysis during Cycle 1 of each phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":"71.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":"63.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":"59.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"529","spread":"59.7"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)","description":"Tmax,ss was assessed by population PK analysis during Cycle 1 of each phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":146,"n":265},"commonTop":["Pyrexia","Febrile neutropenia","Diarrhoea","Hypokalaemia","Nausea"]}}}